View this email in your browser

MORE TIME, MORE OPTIONS

CLINICAL TRIALS NEWSLETTER

PRESENTED BY FIGHTCRC WITH SUPPORT FROM MERCK

A metastatic colorectal cancer diagnosis comes with a lot of decisions, and the first treatment decision may be the most defining one you make. Before you start, you have more options than you might know. **This month, we're focused on what it means to navigate first-line treatment in metastatic CRC: what the term actually means, why timing matters, and what's available right now for patients ready to explore every possibility.**

We want to hear from you!

What do you want to see in our Clinical Trials Newsletter?

LET US KNOW!

FEATURED STORY

First-Line Treatment in Metastatic CRC — Why the Conversation Starts Now

When colorectal cancer is metastatic, the first treatment decision carries significant weight. "First-line treatment" refers to the very first course of therapy you receive after a metastatic CRC diagnosis. It sounds straightforward, but the decision is shaped by

your tumor's biology, your overall health, your goals, and increasingly, by what is being studied in clinical trials right now.

Some clinical trial options are only available before treatment begins. Once therapy starts, that window can close quickly.

Comprehensive biomarker testing, including RAS, BRAF V600E, MSI/dMMR, and HER2, plays a critical role in determining both standard treatment options and clinical trial eligibility. Asking about trials early is one of the most informed steps a patient can take.

Fight CRC is committed to helping patients and care partners understand what first-line treatment means, what questions to ask before starting, and what options may be available at this important stage of care.

To learn more: **Register for our August 27 webinar: Clinical Trials and First-Line Metastatic CRC.**

Join Fight CRC for a free webinar for patients, survivors, and care partners. Dr. Christopher Lieu (University of Colorado School of Medicine) and Fight CRC

Research Advocate Bill Thach will walk through first-line treatment decisions, how clinical trials fit into care planning, and what to ask your care team before starting treatment.

Supported by Pfizer. Content developed independently by Fight CRC.

JOIN US ON AUGUST 27

Listen to the audio version of this newsletter!

CLINICAL TRIAL ROUNDUP

Open Trials for Every Stage

This month's roundup features clinical trials for patients with metastatic colorectal cancer across a range of biomarker profiles and treatment stages. Whether you're considering your first treatment or planning what comes next, these are conversations worth having with your care team before treatment decisions are made.

EXPLORE THE AUGUST CLINICAL TRIALS BLOG

Disclaimer: *Inclusion in this list does not imply endorsement or a guaranteed benefit. Always consult your healthcare provider to determine whether a clinical trial is appropriate for you.*

SPOTLIGHT

Symbiotic-GI-03: Targeting Two Pathways at Once in First-Line Treatment

Pfizer's Phase 3 double-blind clinical trial is evaluating a potential first-line treatment for patients with metastatic colorectal cancer who have not received prior anticancer treatment for metastatic disease.

The study medicine, PF-08634404, is an investigational bispecific antibody that targets both PD-1 (an immune checkpoint) and VEGF (a protein that supports tumor blood vessel growth) at the same time. It is thought that by binding to these proteins,

the study medicine may help the immune system find and attack the cancer cells while also potentially slowing tumor growth.

If you are diagnosed with metastatic colorectal cancer and have not yet started treatment, ask your doctor whether a first-line clinical trial such as Symbiotic-GI-03 may be an option for you.

LEARN MORE ABOUT THE SYMBIOTIC-GI-03 CLINICAL TRIAL

BEHIND THE RESEARCH

Every month, this newsletter's clinical trial recommendations are reviewed by Fight CRC's Medical Advisory Board (MAB), a group of leading oncologists, gastroenterologists, geneticists, and researchers who volunteer their expertise to keep our patient education grounded in the best available science.

The MAB works alongside our Research Advocacy Training and Support (RATS) volunteers to bridge clinical science and lived experience. Where advocates bring firsthand perspective on navigating CRC, MAB members bring deep research and clinical expertise. Together they make sure what reaches patients is both accurate and genuinely useful.

MEET THE MEDICAL ADVISORY BOARD

ACTION AND AWARENESS

WE NEED YOUR VOICE!

Join us this August during our Summer of Action to help grow the Congressional Colorectal Cancer Caucus and ensure more lawmakers understand the urgent need to prioritize colorectal cancer research, prevention, and patient access.

Whether you have five minutes or an afternoon, there's an opportunity to make your voice heard. **Choose the action** that works best for you, and we'll provide everything you need to get started, including talking points, templates, and resources so you can advocate with confidence.

Want to make your voice heard? **Join our next Advocacy Action Hour August 20 (tomorrow) at 8:30 p.m. ET** and learn how you can help drive change for the colorectal cancer community.

Prefer Listening? Play the Audio Version

FIGHT CRC SCREENING QUIZ

Take the Quiz!

CHATCRC

Ask Now!

FIGHT CRC PROVIDER FINDER

Search Now!

DONATE TO SUPPORT OUR RESEARCH

Thank you to our sponsors for this month's Clinical Trials:

Bristol Myers Squibb™

Johnson&Johnson

MERCK

Summit therapeutics™

© Copyright 2026 Fight Colorectal Cancer
FightCRC.org

Want to change how you receive these emails?

You can update your preferences or unsubscribe